CONTINGENCY

3 Months Ended

Jun. 30, 2011

CONTINGENCY

NOTE 11 - CONTINGENCY

On February 28, 2011, the Company entered into a purchase agreement with L.Y. Research Corp., a New Jersey corporation.   Pursuant to the terms of the purchase agreement, the Company acquires a patent from L.Y. (HK) Biotech Limited, in exchange for 75,865,631 shares of the Company’s common stock. Pursuant to the terms of the purchase agreement, the total consideration was paid and will be $56,140,567.  However, the occurrences of $23,391,902 are considered as contingent considerations.